Cylene Pharmaceuticals, Inc. and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
3/6/2013 9:32:34 AM
More...
|
New Drug Stunts Tumor Growth, Cylene Pharmaceuticals, Inc. Reveals
7/18/2012 7:46:19 AM
More...
|
Cylene Pharmaceuticals, Inc. Release: Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
7/10/2012 10:59:18 AM
More...
|
Cylene Pharmaceuticals, Inc. Builds on Success, Presents Second CK2 Inhibitor at American Association for Cancer Research Meeting
4/4/2012 9:37:38 AM
More...
|
Cylene Pharmaceuticals, Inc. Builds on Success, Presents Second CK2 Inhibitor at American Association for Cancer Research Meeting
4/3/2012 11:24:27 AM
More...
|
Cylene Pharmaceuticals, Inc. First-in-Class Agents Show Promise in High Risk Blood Cancers at American Society of Hematology
12/13/2011 11:04:14 AM
More...
|
Cylene Pharmaceuticals, Inc. Advances Breakthrough p53 Activator Toward the Clinic
10/13/2011 10:29:55 AM
More...
|
Cylene Pharmaceuticals, Inc. Presents Encouraging Clinical Data for Oral CK2 Inhibitor at American Society of Clinical Oncology
6/6/2011 10:23:59 AM
More...
|
Cylene Pharmaceuticals, Inc. Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hypertension Meeting
12/6/2010 7:59:54 AM
More...
|
Cylene Pharmaceuticals, Inc. to Present Advances with Industry's Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
11/16/2010 7:29:26 AM
More...
|
|